{"count": 16, "results": [{"_id": "31539054", "pmid": 31539054, "title": "Limited reproducibility of MUCH and WUCH: evidence from the ELSA study.", "journal": "Eur Heart J", "authors": ["Mancia G", "Facchetti R", "Cuspidi C", "Bombelli M", "Corrao G", "Grassi G"], "date": "2020-04-21T00:00:00Z", "doi": "10.1093/eurheartj/ehz651", "meta_date_publication": "2020 Apr 21", "meta_volume": "41", "meta_issue": "16", "meta_pages": "1565-1571", "score": 50233.49, "text_hl": "METHODS AND RESULTS: Reproducibility of MUCH and @DISEASE_White_Coat_Hypertension @DISEASE_MESH:D059466 @@@WUCH@@@ was assessed in 1664 @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ recruited for the European @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@Lacidipine@@@ Study on @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ and treated with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ or @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ (+-additional drugs) during a 4-year period. ", "citations": {"NLM": "Mancia G, Facchetti R, Cuspidi C, Bombelli M, Corrao G, Grassi G. Limited reproducibility of MUCH and WUCH: evidence from the ELSA study. Eur Heart J. 2020 Apr 21;41(16):1565-1571. PMID: 31539054", "BibTeX": "@article{31539054, title={Limited reproducibility of MUCH and WUCH: evidence from the ELSA study.}, author={Mancia G and Facchetti R and Cuspidi C and Bombelli M and Corrao G and Grassi G}, journal={Eur Heart J}, volume={41}, number={16}, pages={1565-1571}}"}}, {"_id": "6130595", "pmid": 6130595, "title": "The effect on HDL cholesterol of oxprenolol and atenolol.", "journal": "Scand J Clin Lab Invest", "authors": ["Kjeldsen SE", "Eide I", "Leren P", "Foss OP", "Holme I", "Eriksen IL"], "date": "1982-09-01T00:00:00Z", "meta_date_publication": "1982 Sep", "meta_volume": "42", "meta_issue": "5", "meta_pages": "449-53", "score": 50062.414, "text_hl": "The HDL cholesterol lowering effect of @CHEMICAL_Oxprenolol @CHEMICAL_MESH:D010096 @@@oxprenolol@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ observed in the present study may have clinical importance since such metabolic side effects have been postulated to counteract the beneficial effect of blood pressure reduction on development of @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerosis@@@ and @DISEASE_Coronary_Disease @DISEASE_MESH:D003327 @@@coronary heart disease@@@ in mild @DISEASE_Essential_Hypertension @DISEASE_MESH:D000075222 @@@essential hypertension@@@.", "citations": {"NLM": "Kjeldsen SE, Eide I, Leren P, Foss OP, Holme I, Eriksen IL. The effect on HDL cholesterol of oxprenolol and atenolol. Scand J Clin Lab Invest. 1982 Sep;42(5):449-53. PMID: 6130595", "BibTeX": "@article{6130595, title={The effect on HDL cholesterol of oxprenolol and atenolol.}, author={Kjeldsen SE and Eide I and Leren P and Foss OP and Holme I and Eriksen IL}, journal={Scand J Clin Lab Invest}, volume={42}, number={5}, pages={449-53}}"}}, {"_id": "8367379", "pmid": 8367379, "title": "Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation.", "journal": "Pharmacol Res", "authors": ["Corsini A", "Quarato P", "Raiteri M", "Paubert-Braquet M", "Nguyen G", "Picquot S", "Bourgain RH", "Fumagalli R", "Paoletti R"], "date": "1993-05-01T00:00:00Z", "doi": "10.1006/phrs.1993.1030", "meta_date_publication": "1993 May-Jun", "meta_volume": "27", "meta_issue": "4", "meta_pages": "299-307", "score": 50059.586, "text_hl": "Effect of the @CHEMICAL_Nifedipine @CHEMICAL_MESH:D009543 @@@nifedipine@@@-@<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ association on arterial myocyte migration and proliferation.", "citations": {"NLM": "Corsini A, Quarato P, Raiteri M, Paubert-Braquet M, Nguyen G, Picquot S, Bourgain RH, Fumagalli R, Paoletti R. Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res. 1993 May-Jun;27(4):299-307. PMID: 8367379", "BibTeX": "@article{8367379, title={Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation.}, author={Corsini A and Quarato P and Raiteri M and Paubert-Braquet M and Nguyen G and Picquot S and Bourgain RH and Fumagalli R and Paoletti R}, journal={Pharmacol Res}, volume={27}, number={4}, pages={299-307}}"}}, {"_id": "8852539", "pmid": 8852539, "title": "Potential modification of plaque behavior through the European lacidipine study on atherosclerosis.", "journal": "J Cardiovasc Pharmacol", "authors": ["Bond MG", "Mercuri M"], "date": "1995-01-01T00:00:00Z", "meta_date_publication": "1995", "meta_volume": "25 Suppl 3", "meta_issue": "", "meta_pages": "S11-6", "score": 50058.156, "text_hl": "The European @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@Lacidipine@@@ Study on @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ (ELSA) has been designed to compare the effects of two antihypertensive agents, the @CHEMICAL_Calcium @CHEMICAL_MESH:D002118 @@@calcium@@@ antagonist @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ and the beta-blocker @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@, on the development of @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerosis@@@ in @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ stratified according to the presence of @DISEASE_Carotid_Stenosis @DISEASE_MESH:D016893 @@@carotid plaques@@@, or the presence or absence of carotid artery intima-media thickening. ", "citations": {"NLM": "Bond MG, Mercuri M. Potential modification of plaque behavior through the European lacidipine study on atherosclerosis. J Cardiovasc Pharmacol. 1995;25 Suppl 3():S11-6. PMID: 8852539", "BibTeX": "@article{8852539, title={Potential modification of plaque behavior through the European lacidipine study on atherosclerosis.}, author={Bond MG and Mercuri M}, journal={J Cardiovasc Pharmacol}, volume={25 Suppl 3}, pages={S11-6}}"}}, {"_id": "19124398", "pmid": 19124398, "title": "Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.", "journal": "Ther Adv Cardiovasc Dis", "authors": ["Stumpe KO", "Agabiti-Rosei E", "Zielinski T", "Schremmer D", "Scholze J", "Laeis P", "Schwandt P", "Ludwig M", "MORE study investigators"], "date": "2007-12-01T00:00:00Z", "doi": "10.1177/1753944707085982", "meta_date_publication": "2007 Dec", "meta_volume": "1", "meta_issue": "2", "meta_pages": "97-106", "score": 50055.96, "text_hl": "OBJECTIVE: The Multicentre @CHEMICAL_olmesartan @CHEMICAL_MESH:C437965 @@@Olmesartan@@@ @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerosis@@@ Regression Evaluation (MORE) study was a double-blind trial in @SPECIES_9606 @@@patients@@@ with @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ at increased cardiovascular risk with carotid wall thickening and a defined @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerotic@@@ plaque that used non-invasive 2- and 3-dimensionaL (D) ultrasound (US), to compare the effects of a 2-year treatment based on either @CHEMICAL_Olmesartan_Medoxomil @CHEMICAL_MESH:D000068557 @@@olmesartan medoxomil@@@ or @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ on common carotid (CC) intima-media thickness (IMT) and plaque volume (PV). ", "citations": {"NLM": "Stumpe KO, Agabiti-Rosei E, Zielinski T, Schremmer D, Scholze J, Laeis P, Schwandt P, Ludwig M, MORE study investigators. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis. 2007 Dec;1(2):97-106. PMID: 19124398", "BibTeX": "@article{19124398, title={Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.}, author={Stumpe KO and Agabiti-Rosei E and Zielinski T and Schremmer D and Scholze J and Laeis P and Schwandt P and Ludwig M and MORE study investigators}, journal={Ther Adv Cardiovasc Dis}, volume={1}, number={2}, pages={97-106}}"}}, {"_id": "17984668", "pmid": 17984668, "title": "Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.", "journal": "J Hypertens", "authors": ["Zanchetti A", "Hennig M", "Baurecht H", "Tang R", "Cuspidi C", "Carugo S", "Mancia G"], "date": "2007-12-01T00:00:00Z", "doi": "10.1097/HJH.0b013e3282f063d5", "meta_date_publication": "2007 Dec", "meta_volume": "25", "meta_issue": "12", "meta_pages": "2463-70", "score": 50055.04, "text_hl": "BACKGROUND: The European @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@Lacidipine@@@ Study on @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ (ELSA) randomized 2334 @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensive@@@ @SPECIES_9606 @@@patients@@@ to either the lipophilic @CHEMICAL_Calcium @CHEMICAL_MESH:D002118 @@@calcium@@@ antagonist @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ or the beta-blocker @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ for 4 years. ", "citations": {"NLM": "Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S, Mancia G. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. J Hypertens. 2007 Dec;25(12):2463-70. PMID: 17984668", "BibTeX": "@article{17984668, title={Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.}, author={Zanchetti A and Hennig M and Baurecht H and Tang R and Cuspidi C and Carugo S and Mancia G}, journal={J Hypertens}, volume={25}, number={12}, pages={2463-70}}"}}, {"_id": "12455152", "pmid": 12455152, "title": "Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine.", "journal": "Drugs R D", "authors": ["Haller H", "Cosentino F", "Lüscher TF"], "date": "2002-01-01T00:00:00Z", "doi": "10.2165/00126839-200203050-00005", "meta_date_publication": "2002", "meta_volume": "3", "meta_issue": "5", "meta_pages": "311-23", "score": 50049.9, "text_hl": "The European @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@Lacidipine@@@ Study on @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ (ELSA) showed that @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ was able to slow the progression of @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerosis@@@, measured as carotid intimato-media thickness, by 40% compared with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ (p = 0.0073). ", "citations": {"NLM": "Haller H, Cosentino F, Lüscher TF. Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine. Drugs R D. 2002;3(5):311-23. PMID: 12455152", "BibTeX": "@article{12455152, title={Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine.}, author={Haller H and Cosentino F and Lüscher TF}, journal={Drugs R D}, volume={3}, number={5}, pages={311-23}}"}}, {"_id": "8458681", "pmid": 8458681, "title": "Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.", "journal": "Int J Clin Pharmacol Ther Toxicol", "authors": ["Sasaki J", "Koga S", "Kato K", "Takii M", "Sakai K", "Kawasaki K", "Kagimoto M", "Doi Y", "Takada K", "Sakaue A"], "date": "1993-02-01T00:00:00Z", "meta_date_publication": "1993 Feb", "meta_volume": "31", "meta_issue": "2", "meta_pages": "83-8", "score": 50048.734, "text_hl": "There were no significant changes in serum @CHEMICAL_Lipids @CHEMICAL_MESH:D008055 @@@lipids@@@, apolipoproteins, lipoproteins or @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerotic@@@ indices after both @CHEMICAL_ceronapril @CHEMICAL_MESH:C054518 @@@SQ29,852@@@ and @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. ", "citations": {"NLM": "Sasaki J, Koga S, Kato K, Takii M, Sakai K, Kawasaki K, Kagimoto M, Doi Y, Takada K, Sakaue A. Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol. Int J Clin Pharmacol Ther Toxicol. 1993 Feb;31(2):83-8. PMID: 8458681", "BibTeX": "@article{8458681, title={Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.}, author={Sasaki J and Koga S and Kato K and Takii M and Sakai K and Kawasaki K and Kagimoto M and Doi Y and Takada K and Sakaue A}, journal={Int J Clin Pharmacol Ther Toxicol}, volume={31}, number={2}, pages={83-8}}"}}, {"_id": "17414674", "pmid": 17414674, "title": "Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis.", "journal": "J Hypertens", "authors": ["Mancia G", "Parati G", "Bilo G", "Maronati A", "Omboni S", "Baurecht H", "Hennig M", "Zanchetti A"], "date": "2007-05-01T00:00:00Z", "doi": "10.1097/HJH.0b013e32805bf8ce", "meta_date_publication": "2007 May", "meta_volume": "25", "meta_issue": "5", "meta_pages": "1087-94", "score": 50044.832, "text_hl": "METHODS: Ambulatory BP monitoring and clinic BP (CBP) measurements were performed at baseline and at yearly intervals over a 4-year follow-up period in 1523 @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertensives@@@ (56.1 +/- 7.6 years) randomized to treatment with @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ or @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ in the European @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@Lacidipine@@@ Study on @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ (ELSA). ", "citations": {"NLM": "Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, Hennig M, Zanchetti A. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2007 May;25(5):1087-94. PMID: 17414674", "BibTeX": "@article{17414674, title={Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis.}, author={Mancia G and Parati G and Bilo G and Maronati A and Omboni S and Baurecht H and Hennig M and Zanchetti A}, journal={J Hypertens}, volume={25}, number={5}, pages={1087-94}}"}}, {"_id": "14524737", "pmid": 14524737, "title": "Lacidipine: a review of its use in the management of hypertension.", "journal": "Drugs", "authors": ["McCormack PL", "Wagstaff AJ"], "date": "2003-01-01T00:00:00Z", "doi": "10.2165/00003495-200363210-00008", "meta_date_publication": "2003", "meta_volume": "63", "meta_issue": "21", "meta_pages": "2327-56", "score": 50044.36, "text_hl": "During long-term treatment for 4 or 5 years in @SPECIES_9606 @@@patients@@@ with isolated systolic @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ or @DISEASE_Essential_Hypertension @DISEASE_MESH:D000075222 @@@essential hypertension@@@, the incidence of cardiovascular events and mortality with @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ was similar to that with @CHEMICAL_Chlorthalidone @CHEMICAL_MESH:D002752 @@@chlorthalidone@@@ or @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@. The European @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@Lacidipine@@@ Study on @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@Atherosclerosis@@@ (ELSA), in which 2334 @SPECIES_9606 @@@patients@@@ with @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@ were randomised to 4 years of therapy with @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ 4-6 mg/day or the beta-blocker @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ 50-100 mg/day, demonstrated significantly lower @<m>DISEASE_Atherosclerosis</m> @DISEASE_MESH:D050197 @@@atherosclerotic@@@ progression and plaque formation with @CHEMICAL_lacidipine @CHEMICAL_MESH:C060285 @@@lacidipine@@@ compared with @<m>CHEMICAL_Atenolol</m> @CHEMICAL_MESH:D001262 @@@atenolol@@@ in @SPECIES_9606 @@@patients@@@ completing the full 4 years of the study. ", "citations": {"NLM": "McCormack PL, Wagstaff AJ. Lacidipine: a review of its use in the management of hypertension. Drugs. 2003;63(21):2327-56. PMID: 14524737", "BibTeX": "@article{14524737, title={Lacidipine: a review of its use in the management of hypertension.}, author={McCormack PL and Wagstaff AJ}, journal={Drugs}, volume={63}, number={21}, pages={2327-56}}"}}]}